Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols
Tóm tắt
Từ khóa
Tài liệu tham khảo
Schmid I, Schweinitz DV. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma. 2017;4:15–21.
Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Nat Rev Clin Oncol. 2011;8:540–549.
Chuk MK, Mulugeta Y, Roth-Cline M, Mehrotra N, Reaman GH. Enrolling adolescents in disease/target-appropriate adult oncology clinical trials of investigational agents. Clin Cancer Res. 2017;1:9–12.
Herbst R, Gandara D, Hirsch F, et al. Lung Master Protocol (Lung-MAP)—a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21:1514–1524.
Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31:1834–1841.
Woodcock J, Lavange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377:62–70.
Lawrence M, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.
Mody R, Wu Y, Lonigro R, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. J Am Med Assoc. 2015;314:913–925.
Khuong-Quang D, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124:439–47.
Khan T, Karski E, Caron H, et al. Mechanism-of-action-based master trial approach in pediatric oncology. 2017. https://www.focr.org/sites/default/files/iMatrix%20Concept%20Paper.pdf. Accessed September 2017.
Khotskaya Y, Holla V, Farago A, Mills Shaw K, Meric-Bernstam F, Hong D. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66.
US Food and Drug Administration. Guidance for industry. Enrichment strategies for clinical trials to support approval of human drugs and biological products. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf. Published 2012.
Gore L, Ivy P, Balis F, et al. Modernizing clinical trial eligibility: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group. J Clin Oncol. 2017;35:3781–3787.
Allen C, Laetsch T, Mody R, et al. Target and agent prioritization for the Children’s Oncology Group–National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017;109.
European Medicines Agency. Report: Paediatric strategy forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/06/WC500228940.pdf. Published 2017.
Vassal G, Rousseau R, Blanc P, et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Eur J Cancer. 2015;51:218–224.
US Food and Drug Administration. Safety and Innovation Act of 2012, Pub L No. 112-144, 126 Stat 993. https://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed September 2017.
US Food and Drug Administration. Pediatric Research Equity Act of 2003. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm077853.pdf. Accessed September 2017.
Rare pediatric disease priority review vouchers, draft guidance for industry. https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM423325.pdf. Accessed September 2017.
Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for pediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Communities L 378/1.
Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 12 December 2006 amending Regulation 1901/2006 on medicinal products for pediatric use. Official Journal of the European Communities L 378/20.